文献速递神经核医学肿瘤 PET/CT

术前双时点[18F]FET PET可区分成人型弥漫性胶质瘤的CDKN2A/B缺失与PIK3CA突变状态:一项单中心前瞻性研究

Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-10-04

该单中心前瞻性研究于2021年6月至2024年1月纳入76例疑似原发性胶质瘤成人患者,术前行[18F]FET PET/CT双时点显像(注射后20分钟和80分钟)并分析SUVmax与TBRmax及其变化率,结合2021年WHO分类和二代测序数据。结果显示CDKN2A/B缺失患者两次扫描的SUVmax和TBRmax均显著高于无缺失者,PIK3CA突变患者△SUVmax显著更高。

要点

  • CDKN2A/B缺失者早期和延迟扫描SUVmax、TBRmax均高于无缺失者。
  • PIK3CA突变者△SUVmax显著高于无突变者(16.2±11.8 vs 6.7±11.6)。
  • 所有肿瘤均[18F]FET高摄取,TBRmax均大于1.6。

核心结论

  • 在成人型弥漫性胶质瘤中,术前双时点[18F]FET PET/CT可区分CDKN2A/B缺失和PIK3CA突变状态。

研究设计与样本

  • 单中心前瞻性研究,2021年6月至2024年1月纳入76例疑似原发性胶质瘤成人患者。
  • 术前于[18F]FET注射后20分钟(早期)和80分钟(延迟)行静态PET/CT,计算肿瘤 hottest 病灶SUVmax和TBRmax及两时点间百分比变化(△)。
  • 根据2021年WHO分类和二代测序(NGS)数据确定组织病理学,检测12个基因。

主要发现

  • 76例中51例为IDH野生型胶质母细胞瘤,13例为IDH突变型星形细胞瘤,12例为IDH突变型少突胶质细胞瘤。
  • CDKN2A/B缺失患者早期扫描SUVmax为5.7±1.6 vs 无缺失者4.7±1.3(p=0.004),延迟扫描为5.0±1.4 vs 4.4±1.2(p=0.026)。
  • CDKN2A/B缺失患者早期扫描TBRmax为6.5±1.8 vs 无缺失者5.1±1.7(p=0.001),延迟扫描为5.3±1.5 vs 4.3±1.3(p=0.004)。
  • 校正年龄、MRI强化、肿瘤分级和病理类型后,CDKN2A/B缺失与上述SUVmax和TBRmax升高仍相关。
  • PIK3CA突变患者△SUVmax为16.2±11.8 vs 无突变者6.7±11.6(p=0.007),校正年龄、MRI强化、肿瘤分级和病理类型后仍显著更高。

关键数值与推荐

  • 所有肿瘤均[18F]FET高摄取,TBRmax均大于1.6。
  • CDKN2A/B缺失组早期SUVmax 5.7±1.6 vs 无缺失组4.7±1.3(p=0.004),延迟SUVmax 5.0±1.4 vs 4.4±1.2(p=0.026)。
  • CDKN2A/B缺失组早期TBRmax 6.5±1.8 vs 无缺失组5.1±1.7(p=0.001),延迟TBRmax 5.3±1.5 vs 4.3±1.3(p=0.004)。
  • PIK3CA突变组△SUVmax 16.2±11.8 vs 无突变组6.7±11.6(p=0.007)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While [18F]FET PET plays a complementary role in glioma imaging, it needs to be more comprehensively understood for improved characterization of glioma prior to surgery given the evolving landscape of molecular neuropathology. Thus, we investigated the utility of pre-operative dual-time-point [18F]FET PET in correlation with next-generation sequencing (NGS) data in patients with adult-type diffuse glioma (ADG). METHODS: Adult patients who were suspected to have primary glioma were prospectively recruited between June 2021 and January 2024. They underwent pre-operative dual-time-point static PET/CT at 20 min (early) and 80 min (delay) after [18F]FET injection. Semi-quantitative parameters of the hottest lesion (SUVmax) of tumour and the hottest lesion-to-normal brain ratio (TBRmax) were assessed from each summed image. Furthermore, the percentage changes (△) of SUVmax and TBRmax between two images were calculated. Histopathology of glioma was determined according to the 2021 WHO classification and NGS data. RESULTS: This study investigated a dozen genes in 76 patients, of whom 51 had isocitrate dehydrogenase (IDH)-wild-type glioblastoma, 13 had IDH-mutant astrocytoma, and 12 had IDH-mutant oligodendroglioma. Every tumour was [18F]FET-avid having TBRmax more than 1.6. Patients with CDKN2A/B loss had significantly higher values of SUVmax (5.7 ± 1.6 vs. 4.7 ± 1.3, p = 0.004; 5.0 ± 1.4 vs. 4.4 ± 1.2, p = 0.026) and TBRmax (6.5 ± 1.8 vs. 5.1 ± 1.7, p = 0.001; 5.3 ± 1.5 vs. 4.3 ± 1.3, p = 0.004) in both scans than patients without CDKN2A/B loss, even after adjustment for age, MRI enhancement, tumor grade and type of pathology. Furthermore, patients with PIK3CA mutation (16.2 ± 11.8 vs. 6.7 ± 11.6, p = 0.007) had significantly higher △SUVmax than patients without PIK3CA mutation, even after adjustment for age, MRI enhancement, tumor grade, and type of pathology. CONCLUSION: Among the dozen genes investigated in this prospective study in patients with ADG, we found out that CDKN2A/B loss and PIK3CA mutation status could be differentiated by pre-operative dual-time-point [18F]FET PET/CT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lee DY, Oh JS, Kim JW, et al. Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39365462. doi:10.1007/s00259-024-06935-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。